Healthy
Conditions
Keywords
oral mucosal absorption, pharmacokinetics, safety, bicalutamide, Japanese, healthy subject
Brief summary
The purpose of this study is to investigate the presence or absence of oral mucosal absorption of ICI176,334-1
Detailed description
Oral mucosal absorption of ICI176,334-1 in Japanese healthy male subjects
Interventions
DRUGICI176,334-1
Subject will receive single dose of ICI176,334-1
Sponsors
AstraZeneca
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Provision of signed and dated, written informed consent prior to any study specific procedures * Japanese healthy male subjects aged 20 to 45 years * Male subjects should be willing to use barrier contraception ie, condoms, until 3 months after the last dose of investigational product * Have a body mass index (BMI) between 17 and 27 kg/m2 * Eligible based on the physical findings, supine BP, pulse rate, ECG and laboratory assessments, as judged by the investigator(s)
Exclusion criteria
* Presence of any disease under medical treatment * History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, immunological, blood, endocrine, neurological or mental disease to interfere with absorption, distribution, metabolism or excretion of drugs judged by investigator(s) * Presence of any infectious disease, such as bacteria, virus and fungus Presence of allergic disorder, such as asthma, pollen disease or atopic dermatitis, and judged as necessary any medical treatment * Any large surgical history of gastrointestinal tract such as gastric/intestinal resection or suturation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in plasma | Samples are taken at 72 hours after application of the investigational drug |
| To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in saliva | Samples are taken at 72 hours after application of the investigational drug |
Secondary
| Measure | Time frame |
|---|---|
| To assess the safety by assessment of adverse event | Adverse Events will be captured starting from screening up to 14 to 21 days (follow-up) |
| To evaluate the safety by evaluation of vital signs | Collect prior to treatment and up to 14 to 21 days (follow-up) after application of the investigational drug |
| To evaluate the safety by assessment of electrocardiograms (ECGs) | Collect prior to treatment and up to 14 to 21 days (follow-up) after application of the investigational drug |
Outcome results
None listed